Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to seal brain aneurysms without surgery

NCT ID NCT07339358

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called the World Diverter, which is placed inside blood vessels to block blood flow to brain aneurysms (weak spots in artery walls). The goal is to safely seal the aneurysm and prevent rupture. About 72 adults aged 22–80 with unruptured aneurysms in a specific part of the brain artery will be enrolled. The device is not yet proven, so this trial checks its safety and how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 22 to 80 years * Subject, or subject's legal representative provided informed consent * Subject agrees to the requirements of the study, including returning for required follow-up visits * Parent artery diameter of 2.0-5.5 mm distal and proximal to the target IA * Subject has a single target IA in the index procedure with the following characteristics: (1) Unruptured; (2) Located in the ICA from the petrous through the superior hypophyseal segments; and (3) Is a fusiform or saccular wide-necked IA with one of the following characteristics: (a) Small (\< 5 mm) or medium (\>5-10 mm) size with a neck width ≥ 4.0 mm or a dome-to-neck ratio of \< 2; OR (b) Large (\>10-25 mm) or giant (\>25 mm) size Exclusion Criteria: * A subarachnoid or intracerebral hemorrhage in the 60 days preceding the index procedure * A bleeding disorder or a platelet count of less than 100x103/mm3 or INR \>1.5 * A contraindication to or inability to tolerate antiplatelet therapy * An allergy to radiographic contrast agents * An allergy to  nickel, titanium, platinum, tungsten, or stainless steel * An allergy to local or general anesthesia * A history of untreated atrial fibrillation, untreated/uncontrollable hypertension, or other stroke risk factors * A history of deep vein thrombosis or pulmonary embolism * A history of heart failure, dilated cardiomyopathy, or congenital heart conditions * Hypercoagulopathy or a hemorrhagic or coagulation deficiency refractory to medical therapy or subject refuses treatment with blood products * Suffered a stroke within 180 days preceding the index procedure * Had major surgery within the 30 days preceding or planned for the 180 days following the index procedure, including but not limited to intracranial stenting or coiling * Target aneurysm has been previously treated with clipping, coiling, or flow diversion * Had previous stenting of or implant in parent artery proximal to the target aneurysm that could interfere with delivery or performance of study device * Asymptomatic extradural aneurysms requiring treatment * Contraindication to computed tomography (CT) or magnetic resonance (MR) * An unstable neurological deficit (i.e., worsening of a clinical condition within the 30 days preceding the index procedure) * Evidence of an active systemic infection (including COVID-19) at index procedure * Dementia or other cognitive condition limiting their ability to participate in the study * A condition that may limit survival to less than 12 months post-index procedure * Serum creatinine ≥2.5 mg/dL * Had radiation or chemotherapy treatment either currently or within the 60 days preceding the index procedure * Current enrollment in a separate clinical trial * Another condition(s) that, in the opinion of the Investigator, could interfere with the ability to perform a safe or effective procedure * Current pregnancy or plan to become pregnant within the 12 months following the index procedure, or be currently breastfeeding Angiographic Exclusion Criteria: * Anatomy not amenable to endovascular treatment, including but not limited to severe vessel tortuosity or stenosis * Parent vessel stenosis is \>50% in the target area * Extracranial stenosis of the carotid artery \>50% * An intracranial mass * More than one vessel segment requiring IA treatment in the 12 months following the index procedure * Target aneurysm is mycotic or dissecting * Target aneurysm is at bifurcation * Target aneurysm will require coiling in addition to flow diversion, in Investigator's opinion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial aneurysm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.